Lipid Regulators Market Size
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Lipid Regulators Market Analysis
The lipid regulators market is expected to register a CAGR of 5.1% over the forecast period.
The pandemic witnessed higher demand for lipid-based supplements owing to their health-beneficial properties. For instance, as per an NCBI study published in October 2021, COVID-19 infection influences the lipid profile, leading to dyslipidemia, which might require appropriate treatment. Owing to its antiviral, anti-inflammatory, immunomodulatory, and cardioprotective activities, statin therapy is considered a valuable tool for improving COVID-19 outcomes. As a result, the consumption of lipid nutritional products increased during the pandemic and positively impacted the market. The market is expected to continue the upward trend over the forecast period as the incidence of cardiovascular diseases has increased owing to the outbreak of the pandemic.
The increasing prevalence of diabetes and cardiac diseases and the growing geriatric population are major drivers for the market. For instance, according to the 2022 American Heart Association (AHA) report, approximately 244.1 million people were living with ischemic heart disease (IHD) around the world, and North Africa and the Middle East, Central and South Asia, and Eastern Europe had the highest prevalence rates of IHD in the world in 2021. This burden of cardiovascular diseases is further expected to increase due to the high prevalence of associated risk factors such as hypertension, obesity, smoking, diabetes, and sedentary lifestyles. Lipids are vital biomolecules in the proper functioning of the metabolism and lipid-altering medication has been proven to reduce cardiovascular risk.
Moreover, with the increase in the elderly age group, the lipid regulators market is expected to surge as this age group is prone to various chronic diseases such as cardiovascular diseases. As per the World Aging Report 2022, the share of the global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. By 2050, the number of people aged 65 years or over worldwide is projected to be more than twice the number of children under age 5 and about the same as the number of children under age 12.
On the other hand, low awareness of lipid regulators and the introduction of low cost generics are likely to hinder the market growth over the forecast period.
Lipid Regulators Market Trends
This section covers the major market trends shaping the Lipid Regulators Market according to our research experts:
The Branded Statins Segment is Expected to Witness Considerable Growth Over the Forecast Period
Branded statins are more effective than other lipid-regulating drugs at lowering LDL-cholesterol concentrations. Some of the statins available in the market include atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin. These branded statins are majorly used for treating dyslipidemia. Dyslipidemia, defined as elevated total or low-density lipoprotein (LDL) cholesterol levels or low levels of high-density lipoprotein (HDL) cholesterol, is an important risk factor for coronary heart disease (CHD) and stroke.
The increasing diabetic population is expected to propel the segment growth as the diabetic population is prone to a higher incidence of dyslipidemia. For instance, as per the World Health Organization, there are over 400.0 million people with diabetes across the world, and its treatment constitutes around 12.0% of the total healthcare expenditure on a global scale. It has emerged as a global epidemic and affected millions worldwide. Currently, about 10% of all diabetes cases are type 1, and the remaining are type 2. The statins competitively inhibit HMG-CoA reductase and lower lipid levels in diseased populations.
North America is Expected to Witness Significant Growth Over the Forecast Period
North America is expected to witness significant growth over the forecast period. The growth is due to factors such as increasing obesity, diabetes, and product launches by the key players. For instance, according to OECD data published in May 2021, the North American countries of the United States and Mexico have one of the highest prevalences of obesity and diabetes in the world. Moreover, being overweight or obese increases the chances of developing the common type of diabetes, type 2 diabetes. As the presence of diabetes increases the risk of dyslipidemia, the demand for lipid regulators is expected to increase over the forecast period. For instance, as per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) data updated in December 2021, more than 34.2 million people had diabetes (or 10.5% of the United States population). The same source also stated that an estimated 26.9 million people of all ages had been diagnosed with diabetes (8.2% of the United States population). Of the people diagnosed with diabetes, 210,000 are children and adolescents younger than 20, including 187,000 with type 1 diabetes.
Key product launches, high concentration of market players or manufacturers' presence, acquisitions and partnerships among major players, and increasing cases of obesity in the United States are some of the factors driving the growth of the lipid regulators market in the country. For instance, according to CDC data updated in May 2022, more than 41.9% of Americans were obese. The prevalence of obesity in the United States increased from 30.5 to 41.9%. The prevalence of severe obesity rose from 4.7% to 9.2% during the same period. The CDC has identified obesity as the leading cause of preventable death in the United States, and it is one of the leading causes of chronic diseases both worldwide and in the United States. Obesity-related disorders, known as comorbidities, include cardiovascular diseases and some cancers. Increasing obesity requires cholesterol control, wherein lipid regulators come into play, which is expected to boost market growth over the forecast period in the United States.
Lipid Regulators Industry Overview
The lipid regulators market is highly competitive and fragmented as the global key players manufacture the majority of the lipid regulators. Market leaders with more funds for research and better distribution systems have established their position in the market. Some market players are AstraZeneca, AbbVie Inc., Amgen, Pfizer, and Teva Pharmaceuticals, among others.
Lipid Regulators Market Leaders
-
AstraZeneca
-
Amgen
-
Pfizer
-
AbbVie Inc
-
Teva Pharmaceuticals
*Disclaimer: Major Players sorted in no particular order
Lipid Regulators Market News
- In May 2022, Sun Pharmaceutical Industries Limited launched a first-in-class oral drug, Bempedoic Acid, in India for reducing low-density lipoprotein (LDL) cholesterol. The company launched the drug under the brand name Brillo.
- In March 2022, Evonik announced the development of a cGMP facility in Hanau, Germany, to manufacture lipids for clinical development and the launch of innovative medicines.
Lipid Regulators Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Diabetes and Cardiac Diseases
- 4.2.2 Growing Geriatric Population
-
4.3 Market Restraints
- 4.3.1 Low Awareness of Lipid Regulators
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
5.1 By Type
- 5.1.1 Statins
- 5.1.1.1 Branded statins
- 5.1.1.2 Statin combinations
- 5.1.1.3 Generic statins
- 5.1.2 Non-statins
- 5.1.2.1 Fibric-acid derivatives
- 5.1.2.2 Bile-acid sequestrants
- 5.1.2.3 Nicotinic acid derivatives
- 5.1.2.4 Other New Products
-
5.2 Geography
- 5.2.1 North America
- 5.2.1.1 United States
- 5.2.1.2 Canada
- 5.2.1.3 Mexico
- 5.2.2 Europe
- 5.2.2.1 Germany
- 5.2.2.2 United Kingdom
- 5.2.2.3 France
- 5.2.2.4 Italy
- 5.2.2.5 Spain
- 5.2.2.6 Rest of Europe
- 5.2.3 Asia-Pacific
- 5.2.3.1 China
- 5.2.3.2 Japan
- 5.2.3.3 India
- 5.2.3.4 Australia
- 5.2.3.5 South Korea
- 5.2.3.6 Rest of Asia-Pacific
- 5.2.4 Middle East and Africa
- 5.2.4.1 GCC
- 5.2.4.2 South Africa
- 5.2.4.3 Rest of Middle East and Africa
- 5.2.5 South America
- 5.2.5.1 Brazil
- 5.2.5.2 Argentina
- 5.2.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AbbVie Inc
- 6.1.2 Amgen
- 6.1.3 Andrx Corporation
- 6.1.4 AstraZeneca
- 6.1.5 Bristol-Myers Squibb
- 6.1.6 Merck KGaA
- 6.1.7 Novartis
- 6.1.8 Pfizer
- 6.1.9 Teva Pharmaceuticals
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityLipid Regulators Industry Segmentation
As per the scope of the report, lipid regulators or lipid-regulating drugs are used to treat dyslipidemia, cardiovascular problems, osteoporosis, and post-menopause complications. This is why these lipid regulators come under the class of most prescribed medications. The lipid regulators market is segmented by Type (Statins (Branded statins, Statin combinations, and Generic statins), and Non-statins (Fibric-acid derivatives, Bile-acid sequestrants, Nicotinic acid derivatives, and Other new products)), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Type | Statins | Branded statins |
| Statin combinations | ||
| Generic statins | ||
| By Type | Non-statins | Fibric-acid derivatives |
| Bile-acid sequestrants | ||
| Nicotinic acid derivatives | ||
| Other New Products | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Lipid Regulators Market Research FAQs
What is the current Global Lipid Regulators Market size?
The Global Lipid Regulators Market is projected to register a CAGR of 5.10% during the forecast period (2024-2029)
Who are the key players in Global Lipid Regulators Market?
AstraZeneca, Amgen, Pfizer, AbbVie Inc and Teva Pharmaceuticals are the major companies operating in the Global Lipid Regulators Market.
Which is the fastest growing region in Global Lipid Regulators Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Lipid Regulators Market?
In 2024, the North America accounts for the largest market share in Global Lipid Regulators Market.
What years does this Global Lipid Regulators Market cover?
The report covers the Global Lipid Regulators Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Global Lipid Regulators Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Lipid Regulators Industry Report
Statistics for the 2024 Global Lipid Regulators market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Lipid Regulators analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
